David King Joins Fluidigm as Vice President, Research and Development, Genomics
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics.
As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, King will drive R&D strategy and execution for all genomics products and systems across the company.
“Fluidigm is a leader in deep, high-parameter analysis of cells and tissue and proprietary microfluidics technology, which form a unique and compelling value proposition,” said Linthwaite. “Building on that foundation, David will help us identify and execute on disruptive opportunities that leverage our considerable genomics leadership in efficiency, flexibility, and cost, including advantages in reagent miniaturization and workflow automation.”
Prior to joining Fluidigm, David was Executive VP, Product Development at IntegenX, a company focused on integration of fluidics, optics, and biochemistry in DNA-based human identity testing. David led collaborations with the FBI, Scotland Yard, and many other organizations worldwide to develop a marketplace for IntegenX products.
Previously, David was VP of Product Development at Affymetrix, where he led introduction of next-generation instrument platforms and genome and transcriptome analysis products. David also served as VP, R&D and Operations at Guava Technologies, where he commercialized research and clinical flow cytometry instrument platforms and applications and led expansion of Guava’s international service and support organization.
“I am thrilled to be joining a company with such a broad base of extraordinary technology that provides industry-leading tools for breakthrough research,” said King. “Fluidigm is well‑positioned to continue to add key value through microfluidic systems and applications, significantly growing the company’s value proposition.”
David is a named inventor on 36 granted and 11 pending U.S. patents. He holds a PhD from Stanford University and a BSc honors degree from University of New South Wales, Australia.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the prospects and potential advantages of Fluidigm technologies and products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including the Fluidigm Quarterly Report on Form 10-Q for the quarter ended March 31, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Contact:
Media:
Mark Spearman
Senior Director, Corporate Communications
Fluidigm Corporation
650 243 6621
mark.spearman@fluidigm.com
Investors:
Agnes Lee
Vice President, Investor Relations
Fluidigm Corporation
650 416 7423
agnes.lee@fluidigm.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Regeneron Pharmaceuticals' (Nasdaq: REGN) REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization
